Zacks: Brokerages Anticipate Catalent (CTLT) Will Announce Earnings of $0.39 Per Share

Equities analysts expect Catalent (NYSE:CTLT) to report earnings per share of $0.39 for the current quarter, Zacks reports. Five analysts have provided estimates for Catalent’s earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.31. Catalent posted earnings per share of $0.38 during the same quarter last year, which would suggest a positive year over year growth rate of 2.6%. The company is scheduled to issue its next quarterly earnings report on Thursday, May 3rd.

On average, analysts expect that Catalent will report full-year earnings of $1.66 per share for the current financial year, with EPS estimates ranging from $1.50 to $1.73. For the next year, analysts forecast that the firm will post earnings of $1.88 per share, with EPS estimates ranging from $1.58 to $1.97. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Catalent.

How to Become a New Pot Stock Millionaire

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The firm had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. Catalent’s revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.27 earnings per share.

A number of research analysts recently commented on the company. KeyCorp raised Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 price target for the company in a report on Wednesday, March 28th. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, April 6th. Stephens downgraded Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. UBS raised Catalent from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 21st. Finally, Raymond James Financial raised Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a report on Wednesday, March 21st. They noted that the move was a valuation call. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $45.75.

CTLT traded down $0.36 on Friday, reaching $40.15. The company’s stock had a trading volume of 249,143 shares, compared to its average volume of 878,536. The company has a market capitalization of $5,332.75, a P/E ratio of 29.67, a P/E/G ratio of 2.18 and a beta of 1.53. Catalent has a 1 year low of $27.56 and a 1 year high of $47.87. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22.

In related news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total value of $379,627.60. Following the sale, the senior vice president now directly owns 46,986 shares in the company, valued at approximately $1,964,014.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.70% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of CTLT. Zions Bancorporation acquired a new position in shares of Catalent during the 3rd quarter valued at $100,000. First Bank & Trust increased its position in shares of Catalent by 54.2% during the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after purchasing an additional 1,323 shares during the period. CAPROCK Group Inc. acquired a new position in shares of Catalent during the 4th quarter valued at $203,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new position in shares of Catalent during the 4th quarter valued at $242,000. Finally, Trexquant Investment LP acquired a new position in shares of Catalent during the 3rd quarter valued at $257,000. Institutional investors own 99.89% of the company’s stock.

WARNING: This piece was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.

Leave a Reply